Wilmington Savings Fund Society’s Neurocrine Biosciences NBIX Stock Holding History

Wilmington Savings Fund Society’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$674	Buy	+4	New	+$593	﹤0.01%	1420
2025 Q3	–	Sell	-88	Closed	-$11.1K	–	1813
2025 Q2	$11.1K	Sell	88 -39	-31%	-$4.47K	﹤0.01%	1609
2025 Q1	$14K	Sell	127 -3,549	-97%	-$450K	﹤0.01%	1556
2024 Q4	$502K	Buy	3,676 +343	+10%	+$42.4K	0.01%	587
2024 Q3	$384K	Buy	+3,333	New	+$457K	0.01%	640

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

SCP

Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Wilmington Savings Fund Society's NBIX Position: Q2 2026 in Review

Wilmington Savings Fund Society opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 4 shares worth $674. The stake represents ﹤0.01% of the portfolio and ranks #1420 among its holdings. This is a return to the name: Wilmington Savings Fund Society previously reported a position in NBIX as recently as Q2 2025.

Wilmington Savings Fund Society first reported a position in NBIX in Q3 2024 and has held it in 5 quarters since. The position peaked at $502K in Q4 2024. 320 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Wilmington Savings Fund Society held 4 shares of Neurocrine Biosciences worth $674 as of Q2 2026.
Neurocrine Biosciences was a new Wilmington Savings Fund Society position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Wilmington Savings Fund Society's portfolio in Q2 2026, its #1420 holding.
Wilmington Savings Fund Society first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 5 quarters since.
Wilmington Savings Fund Society's Neurocrine Biosciences position peaked at $502K in Q4 2024.
320 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Wilmington Savings Fund Society's 13F filing for Q2 2026, filed 28 Jul 2026.